What it is and how it works
From the published literature on Alprostadil; the papers are listed at the end. Research summary, not a recommendation.
What it is
Alprostadil is a synthetic form of prostaglandin E1, a small fatty-acid-derived signalling molecule the body makes naturally; it is not a peptide. It is an FDA-approved medicine in two very different settings: for erectile dysfunction, as an injection into the penis (Caverject, Edex) or a pellet placed in the urethra (MUSE), and as an intravenous infusion (Prostin VR Pediatric) that keeps the ductus arteriosus open in newborns with certain heart defects until surgery.
How it works
Alprostadil binds prostaglandin E receptors (EP receptors, sensors on smooth-muscle cells), which raises the messenger molecule cyclic AMP inside the cell and relaxes the muscle. In the penis this relaxes the smooth muscle of the erectile tissue and its arteries, so blood flows in and an erection follows without needing the nerve signals that oral medicines such as sildenafil depend on. The ductus arteriosus is a blood vessel that lets blood bypass the lungs before birth and normally closes in the first days of life; in babies whose circulation depends on it (ductal-dependent heart defects), alprostadil relaxes its muscular wall and keeps it open. Alprostadil is cleared quickly in the lungs, which is why the newborn use needs a continuous infusion.
What it has been studied for
- Erectile dysfunction by injection into the penis (randomized trials and systematic review)
- Erectile dysfunction by urethral pellet (placebo-controlled trial and review)
- Keeping the ductus arteriosus open in newborns with ductal-dependent congenital heart disease (cohort studies)
- Adverse effects of prostaglandin E1 in newborns, including apnea and stomach outlet problems (cohort studies)
Strength of the evidence
Approved drugAlprostadil is FDA approved for erectile dysfunction (injection and urethral forms) and for maintaining ductal patency in newborns, supported by large placebo-controlled trials in erectile dysfunction.
What the literature reports on safety
In erectile-dysfunction trials the most common effect was penile pain; injection carried a small risk of prolonged erections, priapism (an erection lasting hours that needs urgent treatment), fibrosis (scarring) and bruising, while the urethral form caused no priapism or fibrosis in its main trial but did cause low blood pressure in some men during clinic testing. The newborn product (Prostin VR Pediatric) carries an FDA boxed warning that apnea (pauses in breathing) occurs in about 10 to 12% of newborns with congenital heart defects, most often in the lowest-birth-weight babies and usually in the first hour, so it is given only where breathing support is immediately available; the label also warns of stomach outlet obstruction linked to longer treatment. Cohort studies found adverse events in about half of treated newborns, with apnea and fever more frequent at higher infusion rates.
Key papers
Erectile dysfunction: a global review of intracavernosal injectables. (opens in a new tab)
Review · Duncan C, Omran GJ, et al. · World Journal of Urology (2019) · PMID 30895359
A systematic review that found penile injection therapies effective in 54 to 100% of patients but with early discontinuation in up to 38% and adverse events in up to 26%, and noted that approval of injectable agents is mainly limited to alprostadil.
Intraurethral alprostadil for erectile dysfunction: a review of the literature. (opens in a new tab)
Review · Costa P, Potempa AJ · Drugs (2012) · PMID 23170913
Reviewed the urethral form as an option when oral PDE5-inhibitor medicines fail or cannot be used, reporting fast onset, no priapism or fibrosis in key studies, and higher patient preference than injection.
Randomized trial · Linet OI, Ogrinc FG · New England Journal of Medicine (1996) · PMID 8596569
In a placebo-controlled study of 296 men every alprostadil dose beat placebo, and in a six-month self-injection study of 683 men sexual activity was possible after 94% of injections, with prolonged erections in 5% of men, priapism in 1% and fibrosis in 2%.
Randomized trial · Padma-Nathan H, Hellstrom WJ, et al. · New England Journal of Medicine (1997) · PMID 8970933
In a double-blind trial in 1511 men, 64.9% of in-clinic responders given alprostadil at home had successful intercourse at least once versus 18.6% on placebo; mild penile pain was the most common side effect, low blood pressure occurred in 3.3% in the clinic, and there was no priapism or fibrosis.
Effectiveness of Alprostadil for Ductal Patency. (opens in a new tab)
Cohort study · Gordon CM, Tan JT, Carr RR · Journal of Pediatric Pharmacology and Therapeutics (2024) · PMID 38332962
In 75 newborns with ductal-dependent heart disease, alprostadil kept the duct open effectively in 88%, adverse drug events were common (51%), and apnea and fever were more frequent in the higher of two starting-rate groups.
Cohort study · Ofek Shlomai N, Lazarovitz G, et al. · Children (Basel) (2023) · PMID 37761532
In 82 newborns awaiting heart surgery, gastrointestinal adverse effects rose with the total amount and duration of prostaglandin E1, while apnea, high temperature and fast heart rate were linked to the peak infusion rate.
Sources checked: PubMed (E-utilities esummary and abstracts on every PMID), Prostin VR Pediatric prescribing information boxed warning (Pfizer labeling, labeling.pfizer.com), written 2026-11-06.
No sources yet
None of the three teachers' sources we have indexed discuss Alprostadil yet. This page will fill in as sources are added.
Deeper guided audio lives on What Am I Appreciating Now (leaves this site, opens in a new tab). What Am I Appreciating Now is a separate site run by the same operator; it sells meditation and hypnosis sessions.
Disclaimer: for research purposes only
All content on this page is for research and educational purposes only and is not intended as medical advice. Always consult a qualified healthcare provider before starting any peptide or hormone protocol. You take responsibility for your own protocol.If your path includes peptides, you buy them yourself from an independent licensed provider through a member co-op; we take nothing. How independent access works.